Applied BioMath applies mechanistic modeling to drug R&D to help biotechnology and pharmaceutical companies answer complex, scientific questions and make critical decisions for the advancement of drug candidates. A team of mathematicians, biologists, clinical pharmacologists and
pharmaceutical industry experts, they leverage biology, mathematics, proprietary technologies, HPC, and industry experience to perform massive scale simulations which enable groups to determine best-in-class properties of a clinical candidate, reduce attrition rates, and identify key differentiators from competitors.
Aracari Biosciences’ propriety human Vascularized Micro-Organ (VMO) technology is the first to grow living, perfusable, human blood vessels within a microfluidic 3D platform. Growth of microtumors in these networks recapitulates the physiological delivery of nutrients, drug compounds, or immune cells through living blood vessels, providing a powerful tool for oncology and immune-oncology applications. At Aracari we collaborate with pharmaceutical clients to more accurately and efficiently test drug compounds to de-risk costly preclinical and clinical failures.
For the past 20 years, genOway has aimed to improve the predictability and reliability of preclinical data by designing models of high physiological relevancy to best meet researchers’ needs. With a catalog of humanized immune checkpoint mouse models, and mice featuring the human immune system, genOway possesses a broad set of tools to help decipher the mechanism of action as well as the efficacy and safety of drugs targeting the immune system. Additionally, genOway owns strong intellectual property rights, combining patents and licensing agreements, enabling the company to provide end users the necessary freedom to operate.
Synaffix is a biotech company with a proprietary, clinical-stage ADC platform technology enabling ADCs with improved therapeutic index compared to all 3 major clinical-stage ADC technologies.
Our consolidated technology platform includes GlycoConnect™ antibody conjugation, HydraSpace™ polar spacer and toxSYN™ linker-payload technologies, which can be accessed together by any company with an antibody, to develop their own proprietary, best-in-class ADC.
Our technology out-licensing business has already translated into 3 clinical-stage ADCs, at least 15 distinct ADC programs being developed across our 9 partners and well over $3Bn in total potential value from our out-licensing deals.
At Sampled, our vision is a world where we make it faster and easier for health innovators to improve human health.
Sampled’s virtual lab solution allows companies to harness the economics of outsourcing sample analysis without any capital, operational or labor costs.
Services offered: Sample Storage (long term and short term), Bioprocessing, Bioinformatics, Genetic and Genomic Analytical Services, Cell Culture/Stem Cell Services & Supply Chain, Sample Management and Logistics for Clinical Trials.
We are a competitive and research intelligence database solution designed in partnership with pharmaceutical professionals across the world. We work in targeted therapies such as targeted protein degradation to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Find out more on how we can help you by visiting our website: